London Commodities Consultancy, CRU, To Spotlight Prescriptive Analytics for Monetizing Data at Big Data LDN, The UK’s Leading Data and Analytics Event
The Chief Technology Officer and Co-founder of Pyramid Analytics (Pyramid), Avi Perez, will deliver a session with Will Blake, Chief Technology Officer of CRU, a global provider of business intelligence and consulting services for the global metals, mining and fertilizer industries, at Big Data LDN (London) on Wednesday 21st September at 12:40 p.m. BST at Olympia London. This historic Victorian exhibition space was founded in 1886 and is steps away from the TfL Kensington (Olympia) station.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220916005057/en/
CRU is a global provider of business intelligence and consulting services for the global metals, mining and fertilizer industries. The headquarters of CRU is located in the heart of London. Will Blake, Chief Technology Officer, will discuss how CRU uses prescriptive analytics and Decision Intelligence from Pyramid within its data analytics pipelines, better equipping customers to tackle key decisions within the commodity markets.
Key Points:
- CRU is a leading London commodities consultancy, relied upon by its clients for expert insight and data on the global metals, mining and fertilizer industries.
- Pyramid Analytics is the provider of the Pyramid Decision Intelligence Platform, the only purpose-built, unified Decision Intelligence Platform.
- Will Blake and Avi Perez will discuss how CRU uses prescriptive analytics and Decision Intelligence from Pyramid within its data analytics pipelines, better equipping customers to tackle key decisions within the commodity markets.
- This panel discussion will take place from 12:40 p.m. – 1:10 p.m. BST in the Modern Analytics Theatre at Big Data LDN.
- Join us at stand 435 to meet the Pyramid team, see demos of the Pyramid Platform, and learn how Decision Intelligence can transform your relationship with data.
- Register for your free tickets and find out more about the session here.
Why Attend
Big Data LDN is a major annual event for the UK data and analytics community, regularly bringing together more than 9,000 leading industry experts and practitioners from around the world for two days packed with seminars and exhibits at the Olympia in the heart of London.
-
Wednesday September 21, 12:40 p.m. – 1:10 p.m. in the Modern Analytics Theatre.
Decision Intelligence and Prescriptive Analytics: How CRU uses Pyramid to Drive its Data Analytic Solutions and Help Businesses Make More Informed Decisions
Presenters: Will Blake, Chief Technology Officer at CRU, and Avi Perez, Chief Technology Officer at Pyramid Analytics
Abstract: This session will be a discussion between two CTOs, both experts on data analytics. It will explore how CRU uses the Pyramid Decision Intelligence Platform within its data analytics pipelines, supporting market analysis and commodity price assessments
Blake and Perez will reveal how CRU restructured its approach to analytics, phasing out siloed approaches that relied on different tools and used the Pyramid Decision Intelligence Platform within its data analytics pipelines
Crucially, Decision Intelligence is founded on the principle of helping anyone secure data-driven insights to make faster, more intelligent decisions. CRU put this principle into action, using prescriptive analytics and Decision Intelligence to tackle major challenges such as reducing carbon emissions and other ESG initiatives. In so doing, CRU continues to transform commodity market data into a valuable business asset.
Decision Intelligence is the Next Big Data Analytics Innovation
“Artificial Intelligence (AI) is an increasingly important analytics technology. But AI to date is limited to highly-trained practitioners, and until now, there has been no easy way to integrate the essential AI components of Data Prep, Business Analytics, and Data Science. The Pyramid Decision Intelligence Platform meets this need: its Decision Intelligence solutions go beyond traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. The Pyramid Platform lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards,” said Blake.
In particular, the Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Decision Intelligence is High-Growth Segment of Augmented Analytics
The growth potential of Decision Intelligence is enormous. Gartner predicts that “more than 33%” of large organizations will be using Decision Intelligence by 2023. Similarly, worldwide spending on big data and business analytics (BDA) solutions was forecast to reach $215.7 billion in 2021, an increase of 10.1% over 2020, according to a recent update from IDC. The compound annual growth rate (CAGR) for global BDA spending over the 2021-2025 forecast period is predicted to be 12.8%.
Pyramid is helping to define this growing market.
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Decision Intelligence Platform provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220916005057/en/
Contact information
UK
Alex Izza
Resonance
+44 759 189 9654
pyramidanalytics@resonancecrowd.com
US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com
Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom